Europeiska unionen - slovenska - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomide - multiple skleroza - selektivni imunosupresivi - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Europeiska unionen - slovenska - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - multiplo sklerozo, recidivno-nakazila - imunosupresivi - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Europeiska unionen - slovenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - multiplo sklerozo, recidivno-nakazila - imunosupresivi, selektivno imunosupresivi - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Europeiska unionen - slovenska - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - multiple skleroza - selektivni imunosupresivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 in 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Europeiska unionen - slovenska - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 in 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Slovenien - slovenska - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

actavis group ptc ehf. - valaciklovir - filmsko obložena tableta - valaciklovir 500 mg / 1 tableta - valaciklovir

Slovenien - slovenska - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk d.o.o., ljubljana - valaciklovir - filmsko obložena tableta - valaciklovir 500 mg / 1 tableta - valaciklovir

Slovenien - slovenska - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

generics (uk) ltd. - valaciklovir - filmsko obložena tableta - valaciklovir 500 mg / 1 tableta - valaciklovir

Slovenien - slovenska - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

arrow generics limited - valaciklovir - filmsko obložena tableta - valaciklovir 500 mg / 1 tableta - valaciklovir

Slovenien - slovenska - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

arrow generics limited - valaciklovir - filmsko obložena tableta - valaciklovir 500 mg / 1 tableta - valaciklovir